UNIVERSITY OF CALIFORNIA, IRVINE

UNIVERSITY OF CALIFORNIA, IRVINE logo
🇺🇸United States
Ownership
Private, Subsidiary
Established
1965-01-01
Employees
10K
Market Cap
-
Website
http://www.uci.edu
Clinical Trials
Related News

Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Abnormal Labor

Phase 2
Withdrawn
Conditions
Dysfunctional Labor
Interventions
Drug: Propranolol
Other: IV Placebo
First Posted Date
2006-04-19
Last Posted Date
2019-02-27
Lead Sponsor
University of California, Irvine
Registration Number
NCT00315913
Locations
🇺🇸

Long Beach Memorial Medical Center, Long Beach, California, United States

Improving Tumor Oxygenation in Cervical Cancer

Phase 2
Withdrawn
Conditions
Cervical Cancer
First Posted Date
2005-11-23
Last Posted Date
2018-12-03
Lead Sponsor
University of California, Irvine
Registration Number
NCT00257829

Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma

Phase 2
Completed
Conditions
Cervical Cancer
Interventions
Drug: Topotecan
Drug: Cisplatin
First Posted Date
2005-11-23
Last Posted Date
2018-02-05
Lead Sponsor
University of California, Irvine
Target Recruit Count
12
Registration Number
NCT00257816
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, Orange, California, United States

Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer

Phase 2
Completed
Conditions
Cervical Cancer
First Posted Date
2005-11-22
Last Posted Date
2013-02-08
Lead Sponsor
University of California, Irvine
Target Recruit Count
5
Registration Number
NCT00257348
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, Orange, California, United States

Cellular Immune Augmentation in Colon and Rectal Cancer

Phase 2
Completed
Conditions
Colon Cancer
Rectal Cancer
Interventions
Drug: GM-CSF
First Posted Date
2005-11-22
Last Posted Date
2018-10-31
Lead Sponsor
University of California, Irvine
Target Recruit Count
20
Registration Number
NCT00257322
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, Orange, California, United States

Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma

First Posted Date
2005-11-21
Last Posted Date
2018-01-26
Lead Sponsor
University of California, Irvine
Target Recruit Count
4
Registration Number
NCT00256269
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, Orange, California, United States

Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma

First Posted Date
2005-11-21
Last Posted Date
2019-02-08
Lead Sponsor
University of California, Irvine
Target Recruit Count
4
Registration Number
NCT00256321
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, Orange, California, United States

Resveratrol for Patients With Colon Cancer

Phase 1
Completed
Conditions
Colon Cancer
Cancer
Interventions
Drug: Resveratrol
First Posted Date
2005-11-21
Last Posted Date
2014-06-20
Lead Sponsor
University of California, Irvine
Target Recruit Count
11
Registration Number
NCT00256334
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, Orange, California, United States

Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer

Phase 2
Terminated
Conditions
Head and Neck Cancer
Interventions
Drug: Oxaliplatin
Procedure: Radiation
First Posted Date
2005-11-21
Last Posted Date
2018-05-01
Lead Sponsor
University of California, Irvine
Target Recruit Count
6
Registration Number
NCT00256308
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, Orange, California, United States

Neoadjuvant Treatment of Breast Cancer

First Posted Date
2005-11-16
Last Posted Date
2019-02-28
Lead Sponsor
University of California, Irvine
Target Recruit Count
43
Registration Number
NCT00254592
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, Orange, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy